HC Wainwright Rates Silence Therapeutics (SLN) buy

HC Wainwright maintains a buy rating on Silence Therapeutics, setting a $75 price target, a 896.02% upside from the current price.

By EarningsIQ Research Desk · Published Jun 18, 2026, 3:02 AM EDT · Updated Jun 23, 2026, 10:01 AM EDT

Reviewed by automated data checks against the source data. How we make and check alerts

HC Wainwright rated Silence Therapeutics plc ($SLN) "buy" with a $75 price target on June 17, 2026.

Since the rating, $SLN is up 35.5% after 1 week, up 55.3% after 1 month and up 28.4% to date (from the $6.76 close on Jun 17, 2026).

SLN Silence Therapeutics plc

$8.68 +41.14% year to date

Daily close · Oct 16, 2026

Key Points

On June 17, 2026, HC Wainwright reiterated its buy rating on Silence Therapeutics (NasdaqGM:SLN) with a $75 price target.
HC Wainwright's $75 price target implies 896.02% upside from Silence Therapeutics plc's ($SLN) current $7.53 share price.
Silence Therapeutics, trading at $6.71, has a market cap of $319.3 million and a forward P/E of -17.33.
Richard Ian Griffiths recently purchased shares, and peers like Citadel Advisors increased holdings significantly.

Get $SLN trade alerts by text

We text you when insiders, Congress or big funds trade $SLN. Free.

Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Silence Therapeutics plc alert may contain errors. Disclosures

On June 17, 2026, HC Wainwright reiterated its buy rating on Silence Therapeutics plc (NasdaqGM:SLN), maintaining a price target of $75. Analyst Patrick R. Trucchio continues to see strong potential for the biotechnology company, which specializes in gene-silencing therapies.

Other Institutional Activity in Silence Therapeutics

Several institutional investors have been active in Silence Therapeutics. Nantahala Capital Management increased its holdings by 604,304 shares, bringing its total to 2,146,731 shares valued at approximately $11.3 million. Citadel Advisors made a significant move, adding 990,746 shares to hold a total of 1,234,807 shares worth about $6.5 million. Meanwhile, TCG Crossover Management, Siren, and Redmile Group maintained their positions without change.

Silence Therapeutics plc Stock Down 38.3%

Shares of NasdaqGM:SLN are trading at $6.71. The company has a market cap of approximately $319.3 million and a forward P/E ratio of -17.33, indicating it is not currently profitable. With a beta of 1.484, the stock shows some volatility. Over the past 52 weeks, the stock has ranged from $4.19 to $8.40, with a 50-day moving average of $6.81 and a 200-day moving average of $6.08. The company maintains a strong liquidity position with a current ratio of 9.83 and a quick ratio of 8.82, alongside a low debt-to-equity ratio of 0.275.

12-month forecast

$SLN price target

Silence Therapeutics plc daily closes and this analyst's $75 target. Not advice.

Recent Earnings

Silence Therapeutics reported revenue of $839,000, with a modest growth rate of 1.97%. The company is not yet profitable, reflected in its negative net margin and return on equity of -92.56%. The next earnings report is expected on August 6, 2026.

Insider Buying and Selling at Silence Therapeutics plc

Insider Richard Ian Griffiths has been actively buying shares of Silence Therapeutics. On October 27, 2025, he purchased 8,000 shares, and earlier on August 3, 2025, he bought 20,000 shares. These transactions were not part of a pre-planned trading program.

Analysts Set New Price Targets

On June 17, 2026, HC Wainwright & Co. reiterated its buy rating for Silence Therapeutics, setting a price target of $75. The consensus among analysts is a buy, with an average target price of $31.20 based on five opinions. Other firms like Chardan Capital and Morgan Stanley also maintain buy ratings, with targets of $35 and $25 respectively, while Goldman Sachs has a sell rating with a $3 target.

About Silence Therapeutics

Silence Therapeutics plc is a biotechnology company based in London, UK. It focuses on developing therapies that use short interfering ribonucleic acid (siRNA) to silence specific genes. The company is advancing several candidates, including Divesiran for polycythemia vera and Zerlasiran for cardiovascular disease. Led by CEO Iain Gladstone Ross, the company employs about 88 people.

Bottom Line

HC Wainwright's reiterated buy rating and $75 price target underscore the potential seen in Silence Therapeutics' innovative gene-silencing approach. While the company is not yet profitable, its strong liquidity and ongoing developments in the biotechnology sector make it one to watch. Keep in mind that analyst ratings are based on past filings and may not reflect current conditions.